LitAlert ~~ GeneLit.com

    • Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system.
    • Higashigawa S, Matsubayashi H, Kiyozumi Y, Kado N, Nishimura S, Oishi T, Sugino T, Fushiki K, Shirasu H, Yasui H, Mamesaya N, Fukuzaki N, Kunitomo K, Horiuchi Y, Kenmotsu H, Serizawa M.
    • Jpn J Clin Oncol. 2022 Apr 12:hyac046. doi: 10.1093/jjco/hyac046. Epub ahead of print.
    • Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Apr 12.

    Identifier: NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). (ClinicalTrials.gov)

    • Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
    • Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L.
    • J Clin Oncol. 2022 Apr 11:JCO2101511. doi: 10.1200/JCO.21.01511. Epub ahead of print.
    • UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study.
    • Hopkins C.
    • Precision Oncology News. Cancer Specialties. 2022 Apr 11.

    Identifier: NCT04367675: INO 5401 Vaccination in BRCA1/2 Mutation Carriers. (ClinicalTrials.gov)

    • Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily.
    • Stella S, Vitale SR, Martorana F, Massimino M, Pavone G, Lanzafame K, Bianca S, Barone C, Gorgone C, Fichera M, Manzella L.
    • Cancer Manag Res. 2022 Apr 5;14:1341-1352. doi: 10.2147/CMAR.S348529.
    • Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients.
    • Vidra R, Ciuleanu TE, Nemes A, Pascu O, Heroiu AM, Antone N, Vidrean AI, Oprean CM, Pop LA, Berindan-Neagoe I, Eniu R, Eniu A.
    • Int J Environ Res Public Health. 2022 Apr 4;19(7):4314. doi: 10.3390/ijerph19074314.
    • Predicting Response to Anthracyclines in Ovarian Cancer.
    • Ferrero A, Borghese M, Restaino S, Puppo A, Vizzielli G, Biglia N.
    • Int J Environ Res Public Health. 2022 Apr 2;19(7):4260. doi: 10.3390/ijerph19074260.
    • Demographic Differences Among US Department of Veterans Affairs Patients Referred for Genetic Consultation to a Centralized VA Telehealth Program, VA Medical Centers, or the Community.
    • Scheuner MT, Huynh AK, Chanfreau-Coffinier C, Lerner B, Gable AR, Lee M, Simon A, Coeshott R, Hamilton AB, Patterson OV, DuVall S, Russell MM.
    • JAMA Netw Open. 2022 Apr 1;5(4):e226687. doi: 10.1001/jamanetworkopen.2022.6687.
    • BRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma.
    • Jin TY, Park KS, Nam SE, Yoo YB, Park WS, Yun IJ.
    • Int J Mol Sci. 2022 Mar 29;23(7):3754. doi: 10.3390/ijms23073754.
    • Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With Anticancer Drug Sensitivity in Pancreatic Cancer Cells.
    • Tadehara M, Kato T, Adachi K, Tamaki A, Kesen Y, Sakurai Y, Ichinoe M, Koizumi W, Murakumo Y.
    • Pancreas. 2022 Feb 1;51(2):183-189. doi: 10.1097/MPA.0000000000001975.